are obese, and about 1 in 13 are severely obese
GLP-1RAs are useful tools for the treatment of T2DM, especially for patients aiming weight loss or to hypoglycaemia
It is available through standard pharmacy channels with a prescription
The optimistic scenario assumes: Higher weight-loss efficacy, based on emerging data from trials of AOMs Expanded access to the drug, driving higher uptake assumptions Higher persistency, driven by reduced costs and oral forms of the drug and fewer side effects Lower weight regain after stopping the drug Higher non-weight-loss-related mortality impacts The pessimistic scenario, conversely, considers lower efficacy, lower uptake assumptions, higher and quicker weight regain, and lower non-weight-loss-related mortality impacts
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
But combined with dietary changes and exercise, it may provide a small, legitimate metabolic edge
